29.36 USD
▲+0.03+7.90%
盘后 27.21 0.00%
2026-08-03
市值
$4.25B
市盈率
—
EPS
-0.86
股息率
—
52 周区间
6.21 – 34.39
成交量
1.87M
Beta
1.15
目标价
44.33
52W 低 6.2152W 高 34.39
价格走势
公司简介
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ...